Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Asthma | 142 | 2021 | 438 | 17.580 |
Why?
|
Anti-Asthmatic Agents | 32 | 2018 | 72 | 4.520 |
Why?
|
Bronchodilator Agents | 33 | 2021 | 89 | 4.260 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 22 | 2021 | 142 | 3.330 |
Why?
|
Adrenal Cortex Hormones | 37 | 2021 | 163 | 3.320 |
Why?
|
Adrenergic beta-Agonists | 20 | 2014 | 53 | 2.390 |
Why?
|
Lung | 21 | 2020 | 262 | 2.220 |
Why?
|
Albuterol | 19 | 2018 | 40 | 1.980 |
Why?
|
Eosinophils | 12 | 2019 | 55 | 1.710 |
Why?
|
Humans | 177 | 2021 | 32297 | 1.630 |
Why?
|
Glucocorticoids | 14 | 2020 | 161 | 1.600 |
Why?
|
Sputum | 12 | 2020 | 43 | 1.400 |
Why?
|
Administration, Inhalation | 37 | 2020 | 94 | 1.380 |
Why?
|
Scopolamine Derivatives | 4 | 2013 | 9 | 1.380 |
Why?
|
Budesonide | 7 | 2016 | 11 | 1.370 |
Why?
|
Adult | 98 | 2021 | 9467 | 1.340 |
Why?
|
Receptors, Adrenergic, beta-2 | 11 | 2019 | 36 | 1.260 |
Why?
|
Female | 118 | 2021 | 20126 | 1.260 |
Why?
|
Forced Expiratory Volume | 39 | 2021 | 126 | 1.220 |
Why?
|
Male | 115 | 2021 | 19488 | 1.200 |
Why?
|
Severity of Illness Index | 28 | 2021 | 926 | 1.140 |
Why?
|
Immunotherapy | 2 | 2017 | 83 | 1.130 |
Why?
|
Middle Aged | 79 | 2021 | 11949 | 1.100 |
Why?
|
Respiratory Function Tests | 25 | 2021 | 122 | 1.000 |
Why?
|
Phenotype | 26 | 2020 | 656 | 0.940 |
Why?
|
Polymorphism, Single Nucleotide | 24 | 2019 | 1092 | 0.910 |
Why?
|
Bronchi | 9 | 2021 | 45 | 0.890 |
Why?
|
Adolescent | 42 | 2019 | 3571 | 0.830 |
Why?
|
Polymorphism, Genetic | 7 | 2020 | 194 | 0.830 |
Why?
|
Double-Blind Method | 23 | 2019 | 550 | 0.810 |
Why?
|
Ethanolamines | 5 | 2010 | 16 | 0.810 |
Why?
|
Bronchial Provocation Tests | 6 | 2011 | 14 | 0.760 |
Why?
|
Pulmonary Emphysema | 4 | 2021 | 14 | 0.720 |
Why?
|
Leukotriene Antagonists | 6 | 2016 | 8 | 0.710 |
Why?
|
Disease Progression | 12 | 2020 | 618 | 0.710 |
Why?
|
Child | 31 | 2019 | 2472 | 0.700 |
Why?
|
Genetic Predisposition to Disease | 9 | 2019 | 849 | 0.670 |
Why?
|
Antibodies, Monoclonal | 4 | 2017 | 250 | 0.640 |
Why?
|
Biological Therapy | 2 | 2017 | 22 | 0.620 |
Why?
|
Aged | 37 | 2021 | 10398 | 0.610 |
Why?
|
Anti-Allergic Agents | 1 | 2017 | 7 | 0.610 |
Why?
|
Smoking | 6 | 2021 | 493 | 0.610 |
Why?
|
Immune System Diseases | 1 | 2017 | 2 | 0.600 |
Why?
|
Nasal Polyps | 1 | 2017 | 3 | 0.590 |
Why?
|
Dyspnea | 3 | 2013 | 34 | 0.580 |
Why?
|
European Continental Ancestry Group | 10 | 2020 | 1180 | 0.580 |
Why?
|
Neutrophils | 5 | 2017 | 118 | 0.570 |
Why?
|
Genome-Wide Association Study | 12 | 2019 | 560 | 0.560 |
Why?
|
Young Adult | 26 | 2020 | 2626 | 0.550 |
Why?
|
Pharmacogenetics | 7 | 2015 | 36 | 0.530 |
Why?
|
Inflammation | 10 | 2020 | 542 | 0.530 |
Why?
|
Drug Therapy, Combination | 10 | 2019 | 301 | 0.530 |
Why?
|
Acetates | 5 | 2017 | 15 | 0.520 |
Why?
|
Quinolines | 5 | 2017 | 28 | 0.520 |
Why?
|
Nebulizers and Vaporizers | 3 | 2017 | 14 | 0.510 |
Why?
|
Cell Adhesion Molecules | 2 | 2006 | 47 | 0.490 |
Why?
|
Phosphoproteins | 2 | 2006 | 55 | 0.480 |
Why?
|
Spirometry | 9 | 2019 | 36 | 0.470 |
Why?
|
Hypersensitivity, Immediate | 3 | 2020 | 10 | 0.460 |
Why?
|
Cholinergic Antagonists | 2 | 2010 | 12 | 0.450 |
Why?
|
Th2 Cells | 5 | 2020 | 15 | 0.450 |
Why?
|
Cytokines | 5 | 2020 | 262 | 0.440 |
Why?
|
Eosinophilia | 3 | 2018 | 15 | 0.440 |
Why?
|
Collagen Type III | 2 | 2003 | 13 | 0.430 |
Why?
|
Leukocyte Count | 8 | 2019 | 64 | 0.430 |
Why?
|
Treatment Outcome | 22 | 2021 | 3358 | 0.430 |
Why?
|
African Americans | 9 | 2020 | 1443 | 0.420 |
Why?
|
Respiratory Tract Infections | 3 | 2018 | 42 | 0.420 |
Why?
|
Internet | 3 | 2017 | 203 | 0.410 |
Why?
|
Cholecalciferol | 3 | 2018 | 23 | 0.410 |
Why?
|
Obesity | 7 | 2021 | 1164 | 0.410 |
Why?
|
Fibroblasts | 2 | 2003 | 118 | 0.400 |
Why?
|
Muscle, Smooth | 4 | 2005 | 74 | 0.400 |
Why?
|
Airway Obstruction | 5 | 2019 | 32 | 0.400 |
Why?
|
Vital Capacity | 9 | 2021 | 53 | 0.390 |
Why?
|
Epithelial Cells | 2 | 2003 | 149 | 0.390 |
Why?
|
Bronchoscopy | 6 | 2017 | 57 | 0.390 |
Why?
|
Sex Factors | 7 | 2018 | 674 | 0.380 |
Why?
|
Adenocarcinoma, Papillary | 1 | 2010 | 3 | 0.370 |
Why?
|
Choristoma | 1 | 2010 | 18 | 0.370 |
Why?
|
United States | 17 | 2019 | 3983 | 0.360 |
Why?
|
Intra-Abdominal Fat | 1 | 2010 | 66 | 0.360 |
Why?
|
Health Surveys | 2 | 2009 | 202 | 0.360 |
Why?
|
Nitric Oxide | 9 | 2020 | 121 | 0.360 |
Why?
|
Pancreas | 1 | 2010 | 104 | 0.350 |
Why?
|
Occupational Exposure | 2 | 2018 | 238 | 0.350 |
Why?
|
Immunoglobulin E | 9 | 2019 | 50 | 0.350 |
Why?
|
Research Design | 3 | 2018 | 313 | 0.350 |
Why?
|
Ovarian Neoplasms | 1 | 2010 | 95 | 0.340 |
Why?
|
Treatment Failure | 8 | 2018 | 171 | 0.340 |
Why?
|
Alendronate | 2 | 2019 | 12 | 0.340 |
Why?
|
Genetic Association Studies | 1 | 2009 | 147 | 0.340 |
Why?
|
Receptors, Adrenergic, beta | 2 | 2006 | 13 | 0.340 |
Why?
|
Drug Resistance | 3 | 2020 | 42 | 0.340 |
Why?
|
Chlorofluorocarbons | 1 | 2009 | 1 | 0.340 |
Why?
|
Bronchoalveolar Lavage Fluid | 5 | 2020 | 77 | 0.330 |
Why?
|
Aerosol Propellants | 1 | 2009 | 2 | 0.330 |
Why?
|
Hydrocarbons, Fluorinated | 1 | 2009 | 5 | 0.330 |
Why?
|
Genotype | 12 | 2020 | 742 | 0.330 |
Why?
|
Bronchial Hyperreactivity | 6 | 2015 | 23 | 0.330 |
Why?
|
Cross-Over Studies | 6 | 2019 | 101 | 0.330 |
Why?
|
Anti-Inflammatory Agents | 4 | 2015 | 102 | 0.320 |
Why?
|
Microfilament Proteins | 2 | 2006 | 35 | 0.320 |
Why?
|
Patient Acceptance of Health Care | 4 | 2019 | 171 | 0.320 |
Why?
|
Inflammation Mediators | 2 | 2010 | 103 | 0.310 |
Why?
|
Randomized Controlled Trials as Topic | 4 | 2021 | 511 | 0.310 |
Why?
|
Risk Factors | 12 | 2021 | 3876 | 0.310 |
Why?
|
Case-Control Studies | 10 | 2019 | 911 | 0.300 |
Why?
|
Hypersensitivity | 1 | 2007 | 27 | 0.290 |
Why?
|
Beclomethasone | 6 | 2015 | 8 | 0.290 |
Why?
|
Peak Expiratory Flow Rate | 9 | 2018 | 15 | 0.290 |
Why?
|
Interleukin-13 | 6 | 2012 | 33 | 0.280 |
Why?
|
Prospective Studies | 9 | 2019 | 2274 | 0.280 |
Why?
|
Reproducibility of Results | 4 | 2021 | 779 | 0.280 |
Why?
|
Clinical Trials as Topic | 6 | 2013 | 316 | 0.280 |
Why?
|
Patient Education as Topic | 1 | 2009 | 276 | 0.280 |
Why?
|
Vitamin D Deficiency | 3 | 2018 | 93 | 0.280 |
Why?
|
Hispanic Americans | 3 | 2020 | 949 | 0.270 |
Why?
|
Risk Assessment | 7 | 2019 | 1447 | 0.270 |
Why?
|
Cohort Studies | 11 | 2021 | 1832 | 0.270 |
Why?
|
Th1 Cells | 3 | 2013 | 29 | 0.270 |
Why?
|
Dietary Supplements | 2 | 2018 | 184 | 0.260 |
Why?
|
Animals | 8 | 2017 | 7694 | 0.260 |
Why?
|
Respiratory Mucosa | 2 | 2021 | 14 | 0.260 |
Why?
|
Genetic Loci | 3 | 2019 | 149 | 0.260 |
Why?
|
Arginase | 3 | 2010 | 9 | 0.260 |
Why?
|
Skin | 2 | 2017 | 217 | 0.260 |
Why?
|
Pregnadienediols | 2 | 2015 | 2 | 0.250 |
Why?
|
Paranasal Sinuses | 2 | 2015 | 6 | 0.250 |
Why?
|
Allergy and Immunology | 1 | 2004 | 3 | 0.250 |
Why?
|
Breath Tests | 6 | 2020 | 21 | 0.250 |
Why?
|
Prevalence | 5 | 2019 | 986 | 0.240 |
Why?
|
Tomography, X-Ray Computed | 5 | 2020 | 920 | 0.240 |
Why?
|
Patient Selection | 2 | 2021 | 289 | 0.230 |
Why?
|
Aged, 80 and over | 11 | 2021 | 4050 | 0.230 |
Why?
|
Prognosis | 5 | 2018 | 1523 | 0.230 |
Why?
|
Postural Balance | 1 | 2016 | 180 | 0.230 |
Why?
|
Transforming Growth Factors | 1 | 2003 | 3 | 0.220 |
Why?
|
Antigenic Modulation | 1 | 2003 | 2 | 0.220 |
Why?
|
Pesticides | 1 | 2016 | 202 | 0.220 |
Why?
|
Actins | 1 | 2003 | 53 | 0.220 |
Why?
|
Anti-Bacterial Agents | 3 | 2018 | 309 | 0.220 |
Why?
|
Signal Transduction | 5 | 2018 | 701 | 0.220 |
Why?
|
Transients and Migrants | 1 | 2016 | 293 | 0.210 |
Why?
|
Haplotypes | 4 | 2010 | 224 | 0.210 |
Why?
|
Emigrants and Immigrants | 1 | 2016 | 250 | 0.210 |
Why?
|
Biopsy | 4 | 2017 | 273 | 0.210 |
Why?
|
Practice Guidelines as Topic | 4 | 2017 | 410 | 0.210 |
Why?
|
Child, Preschool | 8 | 2019 | 1281 | 0.210 |
Why?
|
Recurrence | 3 | 2017 | 266 | 0.210 |
Why?
|
Myofibrils | 1 | 2002 | 10 | 0.210 |
Why?
|
Receptors, Glucocorticoid | 3 | 2011 | 8 | 0.200 |
Why?
|
Mucus | 1 | 2021 | 6 | 0.200 |
Why?
|
Age of Onset | 5 | 2012 | 100 | 0.190 |
Why?
|
Disease Management | 3 | 2017 | 131 | 0.190 |
Why?
|
Arginine | 2 | 2012 | 18 | 0.190 |
Why?
|
Comorbidity | 4 | 2017 | 572 | 0.190 |
Why?
|
Aging | 3 | 2017 | 953 | 0.190 |
Why?
|
Iron-Binding Proteins | 1 | 2020 | 5 | 0.190 |
Why?
|
Social Class | 1 | 2021 | 89 | 0.190 |
Why?
|
Amino Acids | 2 | 2019 | 49 | 0.180 |
Why?
|
Age Factors | 8 | 2017 | 1204 | 0.180 |
Why?
|
Minority Groups | 1 | 2021 | 76 | 0.180 |
Why?
|
alpha 1-Antitrypsin | 1 | 2020 | 4 | 0.180 |
Why?
|
Mouth | 1 | 2020 | 25 | 0.180 |
Why?
|
Progesterone Reductase | 1 | 2020 | 3 | 0.180 |
Why?
|
Steroid Isomerases | 1 | 2020 | 3 | 0.180 |
Why?
|
Multienzyme Complexes | 1 | 2020 | 17 | 0.180 |
Why?
|
Idiopathic Pulmonary Fibrosis | 1 | 2019 | 6 | 0.180 |
Why?
|
Lung Diseases, Interstitial | 1 | 2019 | 9 | 0.180 |
Why?
|
Iron | 1 | 2020 | 117 | 0.170 |
Why?
|
Respiratory Sounds | 1 | 2019 | 10 | 0.170 |
Why?
|
Muscarinic Antagonists | 1 | 2019 | 15 | 0.170 |
Why?
|
T-Lymphocyte Subsets | 2 | 2010 | 26 | 0.160 |
Why?
|
Androstadienes | 4 | 2010 | 21 | 0.160 |
Why?
|
Emergency Service, Hospital | 2 | 2019 | 463 | 0.160 |
Why?
|
Corynebacterium | 1 | 2018 | 1 | 0.160 |
Why?
|
T-Lymphocytes | 2 | 2011 | 128 | 0.160 |
Why?
|
Moraxella | 1 | 2018 | 3 | 0.160 |
Why?
|
Aspirin | 1 | 2018 | 65 | 0.160 |
Why?
|
Sleep | 1 | 2019 | 93 | 0.160 |
Why?
|
Cluster Analysis | 3 | 2013 | 131 | 0.160 |
Why?
|
Preoperative Care | 1 | 2019 | 116 | 0.160 |
Why?
|
Gene Expression | 3 | 2021 | 345 | 0.160 |
Why?
|
Patient Care Team | 1 | 2019 | 131 | 0.160 |
Why?
|
Guideline Adherence | 1 | 2019 | 122 | 0.160 |
Why?
|
Hydroxyurea | 1 | 2018 | 3 | 0.160 |
Why?
|
Multivariate Analysis | 6 | 2018 | 696 | 0.160 |
Why?
|
Gonadal Steroid Hormones | 1 | 2018 | 29 | 0.160 |
Why?
|
Interleukin-4 | 2 | 2012 | 22 | 0.160 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2018 | 65 | 0.160 |
Why?
|
Registries | 1 | 2019 | 300 | 0.150 |
Why?
|
Insurance, Health, Reimbursement | 1 | 2017 | 16 | 0.150 |
Why?
|
Indoleacetic Acids | 1 | 2017 | 2 | 0.150 |
Why?
|
Shewanella putrefaciens | 1 | 2017 | 1 | 0.150 |
Why?
|
Laboratories | 1 | 2017 | 16 | 0.150 |
Why?
|
Gram-Negative Bacterial Infections | 1 | 2017 | 14 | 0.150 |
Why?
|
Soft Tissue Infections | 1 | 2017 | 10 | 0.150 |
Why?
|
Pathology | 1 | 2017 | 19 | 0.150 |
Why?
|
Body Mass Index | 6 | 2018 | 921 | 0.150 |
Why?
|
Pyridines | 1 | 2017 | 81 | 0.150 |
Why?
|
Autoimmunity | 1 | 2017 | 34 | 0.150 |
Why?
|
Hand | 1 | 2017 | 67 | 0.150 |
Why?
|
Sleep Apnea Syndromes | 1 | 2017 | 30 | 0.140 |
Why?
|
Membrane Glycoproteins | 2 | 2011 | 110 | 0.140 |
Why?
|
Ibuprofen | 1 | 2016 | 4 | 0.140 |
Why?
|
Emphysema | 1 | 2016 | 7 | 0.140 |
Why?
|
Blood Proteins | 1 | 2016 | 19 | 0.140 |
Why?
|
Delayed-Action Preparations | 1 | 2016 | 35 | 0.140 |
Why?
|
Self Care | 1 | 2017 | 145 | 0.140 |
Why?
|
Acetaminophen | 1 | 2016 | 20 | 0.140 |
Why?
|
Patient Readmission | 1 | 2017 | 115 | 0.140 |
Why?
|
Fluocinolone Acetonide | 2 | 2009 | 7 | 0.140 |
Why?
|
Antibodies, Anti-Idiotypic | 2 | 2006 | 8 | 0.140 |
Why?
|
Biomedical Research | 3 | 2012 | 169 | 0.130 |
Why?
|
Medicare | 1 | 2017 | 206 | 0.130 |
Why?
|
Azithromycin | 1 | 2015 | 15 | 0.130 |
Why?
|
Respiratory System | 2 | 2007 | 13 | 0.130 |
Why?
|
Dose-Response Relationship, Drug | 5 | 2019 | 675 | 0.130 |
Why?
|
Linkage Disequilibrium | 6 | 2012 | 192 | 0.130 |
Why?
|
Skin Diseases | 1 | 2017 | 144 | 0.130 |
Why?
|
African Continental Ancestry Group | 1 | 2017 | 364 | 0.130 |
Why?
|
Secondary Prevention | 1 | 2015 | 65 | 0.130 |
Why?
|
Outpatients | 1 | 2015 | 58 | 0.130 |
Why?
|
Bacteria | 2 | 2016 | 50 | 0.130 |
Why?
|
Peptide Fragments | 1 | 2018 | 422 | 0.130 |
Why?
|
Palliative Care | 1 | 2015 | 54 | 0.120 |
Why?
|
Odds Ratio | 5 | 2015 | 480 | 0.120 |
Why?
|
Predictive Value of Tests | 2 | 2014 | 877 | 0.120 |
Why?
|
Interleukin-1 | 2 | 2005 | 35 | 0.120 |
Why?
|
Pregnenediones | 1 | 2014 | 2 | 0.120 |
Why?
|
Uncertainty | 1 | 2014 | 13 | 0.120 |
Why?
|
Granulocytes | 2 | 2013 | 17 | 0.120 |
Why?
|
Diagnostic Techniques, Respiratory System | 1 | 2014 | 1 | 0.120 |
Why?
|
Clarithromycin | 2 | 2010 | 2 | 0.120 |
Why?
|
Edetic Acid | 1 | 2014 | 9 | 0.120 |
Why?
|
Serum | 1 | 2014 | 20 | 0.120 |
Why?
|
Plasma | 1 | 2014 | 14 | 0.120 |
Why?
|
Zinc Fingers | 1 | 2013 | 10 | 0.120 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2007 | 213 | 0.120 |
Why?
|
Brain Death | 1 | 2014 | 30 | 0.120 |
Why?
|
Patient Preference | 1 | 2014 | 48 | 0.120 |
Why?
|
Quantitative Trait Loci | 3 | 2021 | 143 | 0.120 |
Why?
|
Tissue and Organ Harvesting | 1 | 2014 | 38 | 0.120 |
Why?
|
Drug Administration Schedule | 6 | 2015 | 279 | 0.120 |
Why?
|
Vitamins | 1 | 2014 | 68 | 0.110 |
Why?
|
Repressor Proteins | 1 | 2013 | 52 | 0.110 |
Why?
|
Retrospective Studies | 7 | 2019 | 3514 | 0.110 |
Why?
|
Multifactorial Inheritance | 1 | 2013 | 21 | 0.110 |
Why?
|
Pulmonary Diffusing Capacity | 1 | 2013 | 2 | 0.110 |
Why?
|
Kv Channel-Interacting Proteins | 1 | 2013 | 3 | 0.110 |
Why?
|
Interferon-gamma | 4 | 2010 | 63 | 0.110 |
Why?
|
Receptors, Tumor Necrosis Factor | 2 | 2003 | 49 | 0.110 |
Why?
|
Longitudinal Studies | 3 | 2021 | 786 | 0.110 |
Why?
|
Liver Transplantation | 1 | 2014 | 179 | 0.110 |
Why?
|
Interleukin-4 Receptor alpha Subunit | 1 | 2012 | 6 | 0.110 |
Why?
|
Macrolides | 1 | 2012 | 8 | 0.110 |
Why?
|
Receptors, Interleukin-6 | 1 | 2012 | 18 | 0.100 |
Why?
|
Carrier Proteins | 2 | 2011 | 141 | 0.100 |
Why?
|
Dinoprostone | 3 | 2006 | 34 | 0.100 |
Why?
|
RNA, Ribosomal, 16S | 3 | 2018 | 15 | 0.100 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2020 | 1428 | 0.100 |
Why?
|
Chronic Disease | 3 | 2014 | 406 | 0.100 |
Why?
|
Metered Dose Inhalers | 2 | 2008 | 5 | 0.100 |
Why?
|
Proteins | 1 | 2012 | 150 | 0.100 |
Why?
|
Acute Disease | 3 | 2018 | 255 | 0.090 |
Why?
|
Tobacco Smoke Pollution | 1 | 2011 | 41 | 0.090 |
Why?
|
Liver | 1 | 2014 | 486 | 0.090 |
Why?
|
Incidental Findings | 1 | 2010 | 27 | 0.090 |
Why?
|
Influenza A Virus, H1N1 Subtype | 1 | 2010 | 49 | 0.090 |
Why?
|
Preferred Provider Organizations | 1 | 2010 | 2 | 0.090 |
Why?
|
Health Maintenance Organizations | 1 | 2010 | 14 | 0.090 |
Why?
|
Time Factors | 3 | 2011 | 2181 | 0.090 |
Why?
|
Insurance Claim Review | 1 | 2010 | 28 | 0.090 |
Why?
|
Controlled Clinical Trials as Topic | 1 | 2010 | 11 | 0.090 |
Why?
|
HLA-DQ Antigens | 1 | 2010 | 9 | 0.090 |
Why?
|
HLA-DR Antigens | 1 | 2010 | 9 | 0.090 |
Why?
|
DNA Repair Enzymes | 1 | 2010 | 16 | 0.090 |
Why?
|
Drug Dosage Calculations | 1 | 2010 | 8 | 0.090 |
Why?
|
Lymphatic Metastasis | 1 | 2010 | 172 | 0.090 |
Why?
|
Lymph Node Excision | 1 | 2010 | 92 | 0.090 |
Why?
|
Cross-Sectional Studies | 4 | 2018 | 1522 | 0.090 |
Why?
|
Drug Synergism | 1 | 2010 | 71 | 0.090 |
Why?
|
Superoxide Dismutase | 2 | 2011 | 44 | 0.090 |
Why?
|
Logistic Models | 4 | 2015 | 788 | 0.090 |
Why?
|
Sample Size | 1 | 2009 | 39 | 0.090 |
Why?
|
Allergens | 2 | 2016 | 18 | 0.090 |
Why?
|
Influenza Vaccines | 1 | 2010 | 79 | 0.090 |
Why?
|
Lymphocyte Activation | 2 | 2010 | 90 | 0.090 |
Why?
|
DNA-Binding Proteins | 1 | 2010 | 149 | 0.080 |
Why?
|
Influenza, Human | 1 | 2010 | 124 | 0.080 |
Why?
|
Patients | 1 | 2009 | 47 | 0.080 |
Why?
|
Heat-Shock Proteins | 1 | 2009 | 33 | 0.080 |
Why?
|
Infant | 3 | 2016 | 1076 | 0.080 |
Why?
|
ROC Curve | 3 | 2017 | 171 | 0.080 |
Why?
|
Diagnosis, Differential | 1 | 2010 | 525 | 0.080 |
Why?
|
Cells, Cultured | 5 | 2010 | 846 | 0.080 |
Why?
|
Safety | 1 | 2008 | 78 | 0.080 |
Why?
|
Receptors, Leukotriene | 1 | 2008 | 4 | 0.080 |
Why?
|
Linear Models | 3 | 2018 | 454 | 0.080 |
Why?
|
Receptors, Muscarinic | 1 | 2008 | 10 | 0.080 |
Why?
|
Bronchoconstriction | 1 | 2007 | 3 | 0.080 |
Why?
|
Neutrophil Activation | 1 | 2007 | 5 | 0.080 |
Why?
|
Airway Resistance | 1 | 2007 | 5 | 0.080 |
Why?
|
Amino Acid Substitution | 1 | 2007 | 41 | 0.080 |
Why?
|
North Carolina | 2 | 2017 | 1520 | 0.080 |
Why?
|
Proportional Hazards Models | 2 | 2019 | 759 | 0.070 |
Why?
|
Attitude to Health | 1 | 2009 | 167 | 0.070 |
Why?
|
Apoptosis | 3 | 2006 | 368 | 0.070 |
Why?
|
Physician-Patient Relations | 1 | 2009 | 188 | 0.070 |
Why?
|
Rhinitis | 1 | 2007 | 12 | 0.070 |
Why?
|
Phospholipases A | 2 | 2005 | 28 | 0.070 |
Why?
|
Sinusitis | 1 | 2007 | 19 | 0.070 |
Why?
|
Isoproterenol | 1 | 2006 | 18 | 0.070 |
Why?
|
HSP70 Heat-Shock Proteins | 1 | 2007 | 26 | 0.070 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2010 | 167 | 0.070 |
Why?
|
Exhalation | 2 | 2020 | 5 | 0.070 |
Why?
|
Pituitary-Adrenal System | 1 | 2006 | 24 | 0.070 |
Why?
|
Ocular Hypertension | 1 | 2006 | 10 | 0.070 |
Why?
|
Total Lung Capacity | 2 | 2019 | 2 | 0.070 |
Why?
|
Cataract | 1 | 2006 | 10 | 0.070 |
Why?
|
Hypothalamo-Hypophyseal System | 1 | 2006 | 34 | 0.070 |
Why?
|
Risk | 2 | 2018 | 325 | 0.070 |
Why?
|
Bronchoalveolar Lavage | 2 | 2005 | 16 | 0.070 |
Why?
|
Glaucoma | 1 | 2006 | 23 | 0.070 |
Why?
|
Cost of Illness | 1 | 2006 | 70 | 0.070 |
Why?
|
Phosphodiesterase Inhibitors | 1 | 2005 | 10 | 0.070 |
Why?
|
CpG Islands | 1 | 2005 | 46 | 0.070 |
Why?
|
Alleles | 2 | 2020 | 252 | 0.070 |
Why?
|
Oligodeoxyribonucleotides | 1 | 2005 | 18 | 0.070 |
Why?
|
Asian Continental Ancestry Group | 2 | 2019 | 111 | 0.070 |
Why?
|
MAP Kinase Signaling System | 1 | 2005 | 61 | 0.070 |
Why?
|
Tosyl Compounds | 1 | 2005 | 4 | 0.060 |
Why?
|
Phosphorylation | 1 | 2006 | 234 | 0.060 |
Why?
|
Respiratory Physiological Phenomena | 1 | 2005 | 6 | 0.060 |
Why?
|
Trachea | 1 | 2005 | 55 | 0.060 |
Why?
|
Rhinitis, Allergic, Perennial | 1 | 2005 | 7 | 0.060 |
Why?
|
Dermatitis, Atopic | 1 | 2007 | 104 | 0.060 |
Why?
|
Lung Diseases | 1 | 2005 | 50 | 0.060 |
Why?
|
Pregnancy Complications | 1 | 2006 | 107 | 0.060 |
Why?
|
Regression Analysis | 2 | 2017 | 296 | 0.060 |
Why?
|
Neovascularization, Physiologic | 1 | 2005 | 112 | 0.060 |
Why?
|
Bone Density | 1 | 2006 | 186 | 0.060 |
Why?
|
Interleukin-2 | 3 | 2010 | 33 | 0.060 |
Why?
|
Genetic Variation | 2 | 2021 | 247 | 0.060 |
Why?
|
Follow-Up Studies | 3 | 2018 | 2296 | 0.060 |
Why?
|
Ethnic Groups | 1 | 2007 | 480 | 0.060 |
Why?
|
Interleukin-5 | 1 | 2003 | 7 | 0.060 |
Why?
|
Leukotriene D4 | 1 | 2003 | 2 | 0.060 |
Why?
|
Endpoint Determination | 1 | 2003 | 21 | 0.050 |
Why?
|
Patient Compliance | 2 | 2019 | 227 | 0.050 |
Why?
|
Pregnancy | 1 | 2006 | 1010 | 0.050 |
Why?
|
Killer Cells, Natural | 1 | 2002 | 26 | 0.050 |
Why?
|
Methacholine Chloride | 3 | 2007 | 5 | 0.050 |
Why?
|
Infusions, Parenteral | 1 | 2021 | 68 | 0.050 |
Why?
|
Geography | 1 | 2021 | 35 | 0.050 |
Why?
|
Blotting, Western | 1 | 2002 | 305 | 0.050 |
Why?
|
Algorithms | 2 | 2017 | 497 | 0.050 |
Why?
|
Membrane Proteins | 1 | 2002 | 260 | 0.050 |
Why?
|
Cell Culture Techniques | 1 | 2002 | 176 | 0.050 |
Why?
|
Maximal Midexpiratory Flow Rate | 1 | 2020 | 2 | 0.050 |
Why?
|
Isoelectric Focusing | 1 | 2020 | 5 | 0.050 |
Why?
|
Ferritins | 1 | 2020 | 48 | 0.050 |
Why?
|
TATA Box Binding Protein-Like Proteins | 1 | 2019 | 1 | 0.040 |
Why?
|
Mucin-5B | 1 | 2019 | 3 | 0.040 |
Why?
|
Heterozygote | 1 | 2020 | 57 | 0.040 |
Why?
|
beta Karyopherins | 1 | 2019 | 7 | 0.040 |
Why?
|
Residual Volume | 1 | 2019 | 1 | 0.040 |
Why?
|
Androgens | 1 | 2020 | 34 | 0.040 |
Why?
|
Administration, Oral | 2 | 2014 | 185 | 0.040 |
Why?
|
Base Sequence | 2 | 2013 | 257 | 0.040 |
Why?
|
Isoleucine | 1 | 2019 | 8 | 0.040 |
Why?
|
Tryptophan | 1 | 2019 | 5 | 0.040 |
Why?
|
Placebos | 2 | 2012 | 66 | 0.040 |
Why?
|
Valine | 1 | 2019 | 17 | 0.040 |
Why?
|
Republic of Korea | 1 | 2019 | 12 | 0.040 |
Why?
|
Leucine | 1 | 2019 | 24 | 0.040 |
Why?
|
Drug Combinations | 1 | 2019 | 93 | 0.040 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2019 | 62 | 0.040 |
Why?
|
Receptors, Tumor Necrosis Factor, Type II | 1 | 2019 | 9 | 0.040 |
Why?
|
Receptors, Tumor Necrosis Factor, Type I | 1 | 2019 | 14 | 0.040 |
Why?
|
Metabolomics | 1 | 2019 | 53 | 0.040 |
Why?
|
National Heart, Lung, and Blood Institute (U.S.) | 1 | 2019 | 17 | 0.040 |
Why?
|
Fibrinogen | 1 | 2019 | 43 | 0.040 |
Why?
|
Promoter Regions, Genetic | 1 | 2019 | 213 | 0.040 |
Why?
|
Sleep Apnea, Obstructive | 1 | 2019 | 60 | 0.040 |
Why?
|
Skin Tests | 2 | 2010 | 14 | 0.040 |
Why?
|
Flow Cytometry | 2 | 2010 | 187 | 0.040 |
Why?
|
Polymerase Chain Reaction | 2 | 2010 | 190 | 0.040 |
Why?
|
Vitamin D-Binding Protein | 1 | 2018 | 10 | 0.040 |
Why?
|
Nose | 1 | 2018 | 13 | 0.040 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2018 | 84 | 0.040 |
Why?
|
Puberty | 1 | 2018 | 10 | 0.040 |
Why?
|
Feasibility Studies | 1 | 2019 | 294 | 0.040 |
Why?
|
Incidence | 2 | 2016 | 1207 | 0.040 |
Why?
|
Growth | 1 | 2018 | 7 | 0.040 |
Why?
|
Mouth Mucosa | 1 | 2018 | 31 | 0.040 |
Why?
|
Leukotrienes | 1 | 2018 | 4 | 0.040 |
Why?
|
Current Procedural Terminology | 1 | 2017 | 4 | 0.040 |
Why?
|
C-Reactive Protein | 1 | 2019 | 238 | 0.040 |
Why?
|
Inspiratory Capacity | 1 | 2017 | 3 | 0.040 |
Why?
|
Immunocompetence | 1 | 2017 | 12 | 0.040 |
Why?
|
Patient Care | 1 | 2017 | 37 | 0.040 |
Why?
|
Hand Injuries | 1 | 2017 | 24 | 0.040 |
Why?
|
Foreign Bodies | 1 | 2017 | 30 | 0.040 |
Why?
|
Specialization | 1 | 2017 | 32 | 0.040 |
Why?
|
Workflow | 1 | 2017 | 23 | 0.040 |
Why?
|
Prednisolone | 1 | 2017 | 11 | 0.040 |
Why?
|
Medication Adherence | 1 | 2019 | 161 | 0.040 |
Why?
|
Reference Values | 2 | 2011 | 255 | 0.040 |
Why?
|
Quality of Life | 2 | 2014 | 915 | 0.040 |
Why?
|
RNA, Bacterial | 1 | 2016 | 4 | 0.040 |
Why?
|
Disease Susceptibility | 1 | 2017 | 58 | 0.040 |
Why?
|
Bronchoconstrictor Agents | 2 | 2007 | 3 | 0.040 |
Why?
|
Cell Line | 1 | 2018 | 462 | 0.040 |
Why?
|
ABO Blood-Group System | 1 | 2016 | 20 | 0.030 |
Why?
|
Sex Distribution | 1 | 2017 | 201 | 0.030 |
Why?
|
Chi-Square Distribution | 1 | 2017 | 302 | 0.030 |
Why?
|
Fever | 1 | 2016 | 63 | 0.030 |
Why?
|
Forced Expiratory Flow Rates | 1 | 2015 | 3 | 0.030 |
Why?
|
Socioeconomic Factors | 1 | 2017 | 422 | 0.030 |
Why?
|
RNA, Messenger | 1 | 2018 | 534 | 0.030 |
Why?
|
Drug Resistance, Bacterial | 1 | 2015 | 42 | 0.030 |
Why?
|
Accidental Falls | 1 | 2017 | 219 | 0.030 |
Why?
|
Phospholipases A2 | 2 | 2005 | 22 | 0.030 |
Why?
|
Administration, Intranasal | 1 | 2014 | 33 | 0.030 |
Why?
|
Nutrition Surveys | 1 | 2016 | 149 | 0.030 |
Why?
|
Triamcinolone | 2 | 2005 | 13 | 0.030 |
Why?
|
Ionophores | 2 | 2005 | 5 | 0.030 |
Why?
|
F-Box Proteins | 1 | 2014 | 4 | 0.030 |
Why?
|
Calcimycin | 2 | 2005 | 8 | 0.030 |
Why?
|
Tetradecanoylphorbol Acetate | 2 | 2005 | 13 | 0.030 |
Why?
|
New Jersey | 1 | 2014 | 11 | 0.030 |
Why?
|
Protease Inhibitors | 1 | 2014 | 15 | 0.030 |
Why?
|
Combined Modality Therapy | 2 | 2006 | 567 | 0.030 |
Why?
|
Cell Survival | 2 | 2006 | 301 | 0.030 |
Why?
|
Pain | 1 | 2016 | 305 | 0.030 |
Why?
|
Observer Variation | 1 | 2014 | 109 | 0.030 |
Why?
|
Interferon Regulatory Factor-2 | 1 | 2013 | 5 | 0.030 |
Why?
|
Liver Cirrhosis | 1 | 2014 | 81 | 0.030 |
Why?
|
Fatty Liver | 1 | 2014 | 67 | 0.030 |
Why?
|
STAT4 Transcription Factor | 1 | 2013 | 17 | 0.030 |
Why?
|
Interleukin-12 | 1 | 2013 | 30 | 0.030 |
Why?
|
Single-Blind Method | 2 | 2004 | 200 | 0.030 |
Why?
|
Nuclear Pore | 1 | 2012 | 3 | 0.030 |
Why?
|
Cardiovascular Diseases | 1 | 2021 | 1133 | 0.030 |
Why?
|
Prednisone | 1 | 2012 | 62 | 0.030 |
Why?
|
Biomarkers, Pharmacological | 1 | 2012 | 6 | 0.030 |
Why?
|
3' Untranslated Regions | 1 | 2012 | 25 | 0.030 |
Why?
|
Tissue Donors | 1 | 2014 | 199 | 0.030 |
Why?
|
Homozygote | 1 | 2012 | 60 | 0.030 |
Why?
|
Airway Remodeling | 1 | 2011 | 5 | 0.030 |
Why?
|
Hydrocortisone | 2 | 2002 | 61 | 0.030 |
Why?
|
Myocytes, Smooth Muscle | 1 | 2012 | 73 | 0.030 |
Why?
|
Chromosomes, Human, Pair 12 | 1 | 2011 | 9 | 0.030 |
Why?
|
Chromosomes, Human, Pair 4 | 1 | 2011 | 11 | 0.030 |
Why?
|
Chromosomes, Human, Pair 10 | 1 | 2011 | 9 | 0.030 |
Why?
|
Clinical Protocols | 1 | 2011 | 100 | 0.020 |
Why?
|
Thrombospondins | 1 | 2011 | 7 | 0.020 |
Why?
|
Leptin | 1 | 2011 | 69 | 0.020 |
Why?
|
Receptors, Notch | 1 | 2011 | 17 | 0.020 |
Why?
|
Interleukin-6 | 1 | 2012 | 248 | 0.020 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2010 | 31 | 0.020 |
Why?
|
Phylogeny | 1 | 2010 | 56 | 0.020 |
Why?
|
Chlamydophila pneumoniae | 1 | 2010 | 4 | 0.020 |
Why?
|
Mycoplasma pneumoniae | 1 | 2010 | 5 | 0.020 |
Why?
|
Hydrogen-Ion Concentration | 1 | 2010 | 66 | 0.020 |
Why?
|
Receptors, Cell Surface | 1 | 2011 | 73 | 0.020 |
Why?
|
Lymphocyte Count | 1 | 2010 | 25 | 0.020 |
Why?
|
Hospitalization | 1 | 2014 | 465 | 0.020 |
Why?
|
Proto-Oncogene Proteins | 1 | 2011 | 94 | 0.020 |
Why?
|
Immunophenotyping | 1 | 2010 | 51 | 0.020 |
Why?
|
Environmental Exposure | 1 | 2011 | 92 | 0.020 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2010 | 163 | 0.020 |
Why?
|
Protein Array Analysis | 1 | 2010 | 18 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2011 | 600 | 0.020 |
Why?
|
Discriminant Analysis | 1 | 2009 | 22 | 0.020 |
Why?
|
Recombinant Proteins | 1 | 2010 | 258 | 0.020 |
Why?
|
Vaccination | 1 | 2010 | 137 | 0.020 |
Why?
|
Pilot Projects | 1 | 2010 | 536 | 0.020 |
Why?
|
Gene Frequency | 1 | 2009 | 221 | 0.020 |
Why?
|
Biological Availability | 1 | 2008 | 22 | 0.020 |
Why?
|
Models, Statistical | 1 | 2009 | 176 | 0.020 |
Why?
|
London | 1 | 2007 | 3 | 0.020 |
Why?
|
Lung Volume Measurements | 1 | 2007 | 5 | 0.020 |
Why?
|
Fluorescent Antibody Technique | 1 | 2007 | 94 | 0.020 |
Why?
|
Motor Activity | 1 | 2010 | 327 | 0.020 |
Why?
|
Patient Satisfaction | 1 | 2009 | 245 | 0.020 |
Why?
|
Chromosomes, Human, Pair 6 | 1 | 2007 | 20 | 0.020 |
Why?
|
DNA Primers | 1 | 2007 | 90 | 0.020 |
Why?
|
Cyclic AMP-Dependent Protein Kinase Type II | 1 | 2006 | 1 | 0.020 |
Why?
|
Cyclic AMP-Dependent Protein Kinases | 1 | 2006 | 20 | 0.020 |
Why?
|
Mice | 1 | 2013 | 2524 | 0.020 |
Why?
|
Hypertension | 1 | 2014 | 972 | 0.020 |
Why?
|
Sequence Analysis, DNA | 1 | 2006 | 136 | 0.020 |
Why?
|
Microsomes | 1 | 2005 | 14 | 0.020 |
Why?
|
Cytosol | 1 | 2005 | 27 | 0.020 |
Why?
|
Cyclooxygenase 1 | 1 | 2005 | 23 | 0.020 |
Why?
|
Mitogen-Activated Protein Kinase 1 | 1 | 2005 | 37 | 0.020 |
Why?
|
Mitogen-Activated Protein Kinase 3 | 1 | 2005 | 44 | 0.020 |
Why?
|
Protein Kinases | 1 | 2005 | 27 | 0.020 |
Why?
|
Prostaglandin-Endoperoxide Synthases | 1 | 2005 | 32 | 0.020 |
Why?
|
Protein Kinase C | 1 | 2005 | 32 | 0.020 |
Why?
|
Oxytocics | 1 | 2005 | 14 | 0.020 |
Why?
|
Carcinogens | 1 | 2005 | 36 | 0.020 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 1 | 2005 | 37 | 0.020 |
Why?
|
Cyclooxygenase 2 | 1 | 2005 | 46 | 0.020 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2006 | 148 | 0.020 |
Why?
|
Glutathione Peroxidase | 1 | 2005 | 8 | 0.020 |
Why?
|
NF-kappa B | 1 | 2005 | 82 | 0.020 |
Why?
|
Antigens, CD | 1 | 2005 | 105 | 0.020 |
Why?
|
Cell Count | 1 | 2005 | 52 | 0.020 |
Why?
|
Glutathione | 1 | 2005 | 45 | 0.020 |
Why?
|
Delivery of Health Care | 1 | 2007 | 161 | 0.020 |
Why?
|
Enzyme Inhibitors | 1 | 2005 | 176 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2005 | 95 | 0.020 |
Why?
|
Periodicals as Topic | 1 | 2005 | 101 | 0.010 |
Why?
|
Oxidative Stress | 1 | 2005 | 230 | 0.010 |
Why?
|
BH3 Interacting Domain Death Agonist Protein | 1 | 2003 | 2 | 0.010 |
Why?
|
Caspase 9 | 1 | 2003 | 11 | 0.010 |
Why?
|
Caspase 8 | 1 | 2003 | 14 | 0.010 |
Why?
|
Caspases | 1 | 2003 | 42 | 0.010 |
Why?
|
Immune Sera | 1 | 2002 | 10 | 0.010 |
Why?
|
Tumor Necrosis Factor Decoy Receptors | 1 | 2002 | 5 | 0.010 |
Why?
|
Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2002 | 8 | 0.010 |
Why?
|
Solubility | 1 | 2002 | 38 | 0.010 |
Why?
|
TNF-Related Apoptosis-Inducing Ligand | 1 | 2002 | 25 | 0.010 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2002 | 43 | 0.010 |
Why?
|
Survival Rate | 1 | 2005 | 894 | 0.010 |
Why?
|
Lymphocyte Subsets | 1 | 2002 | 7 | 0.010 |
Why?
|
Probability | 1 | 2002 | 160 | 0.010 |
Why?
|
Cell Division | 1 | 2002 | 98 | 0.010 |
Why?
|
Cell Movement | 1 | 2002 | 171 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2002 | 681 | 0.010 |
Why?
|